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Abstract  
Purpose  
In patients with Alzheimer’s disease (AD), the loss of cerebral nicotinic acetylcholine 
receptors (nAChRs) that are implicated in higher brain functions has been reported. However, it is 
unclear if nAChR deficits occur in association with cognitive impairments. The purpose of this study 
was to assess the relationship between nAChR deficits and cognitive impairments in a mouse model 
of AD (APP/PS2 mice).  
Procedures 
The cognitive abilities of APP/PS2 and wild-type mice (aged 2-16 months) were evaluated 
using the novel object recognition test. Double-tracer autoradiography analyses with 
5-[125I]iodo-A-85380 ([125I]5IA: α4β2 nAChR imaging probe) and 2-deoxy-2-[18F]fluoro-D-glucose 
were performed in both mice of different ages. [123I]5IA-SPECT imaging was also performed in both 
mice at 12 months of age. Furthermore, each age cohort was investigated for changes in cognitive 
ability and expression levels of α7 nAChRs and N-methyl-D-aspartate receptors (NMDARs).   
Results 
No significant difference was found between the APP/PS2 and wild-type mice at 2–6 
months of age in terms of novel object recognition memory; subsequently, however, APP/PS2 mice 
showed a clear cognitive deficit at 12 months of age. [125I]5IA accumulation decreased in the brains 
of 12-month-old APP/PS2 mice i.e., at the age at which cognitive impairments were first observed; 
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this result was supported by a reduction in the protein levels of α4 nAChRs using western blotting. 
nAChR deficits could be noninvasively detected by [123I]5IA-SPECT in vivo. In contrast, no 
significant changes in glycometabolism, expression levels of α7 nAChRs, or NMDARs were 
associated with cognitive impairments in APP/PS2 mice. 
Conclusion 
A decrease in cerebral α4β2 nAChR density could act as a biomarker reflecting cognitive 
impairments associated with AD pathology. 
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Introduction 
Alzheimer’s disease (AD), the most common chronic neurodegenerative disorder, is 
characterized by progressive cognitive impairments associated with a massive loss of synapses and 
neurons in the brain. At present, assessing its progression and severity requires several medical 
evaluations, such as mental state testing [1]. However, the results of these clinical diagnoses are 
frequently obscure because the current diagnosis of AD relies largely on the documentation of mental 
decline [2], and there is currently no definitive diagnostic test for assessing the cerebral functional 
changes that are fundamental to AD pathology. Thus, establishing a biomarker that reflects cognitive 
function is expected to aid in the understanding of the progression of AD and be beneficial clinically. 
Nuclear medical imaging technology is a promising tool for in vivo monitoring of molecular 
processes using positron emission tomography (PET) and single-photon emission computed 
tomography (SPECT). Since this technique is non-invasive and highly quantitative, functional 
neuroimaging is being investigated as a possible method of identifying biomarkers for AD. Although 
much effort has been made to develop imaging probes for Amyloid-β (Aβ), one of the hallmark 
proteins in AD, Aβ-PET imaging in patients with AD showed that the accumulation of Aβ in the 
brain did not necessarily reflect the cognitive decline seen in these patients [3]. Furthermore, cerebral 
2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG)-PET is used clinically as an index of central nervous 
system (CNS) activity. Although [18F]FDG-PET has been found to be better than other imaging 
modalities for AD diagnosis, it is difficult to use to characterize abnormal activity in late-onset 
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patients with AD [4].  
Nicotinic acetylcholine receptors (nAChRs) in the CNS are reported to play an important 
role in higher brain functions, including learning, memory, and recognition [5]. Neuronal α4β2 and 
α7 nAChRs are the two most predominant subtypes expressed in the CNS [6]. Thus, these subtypes 
are thought to be involved in the majority of nAChR signaling, and their dysfunction is believed to 
be related to several CNS disorders, including AD. Moreover, several acetylcholinesterase inhibitors, 
which target nAChRs directly or indirectly, have been developed for the treatment of AD and have 
been used successfully in the prevention of AD disease progression [7]. These inhibitors are reported 
to upregulate α4β2 nAChRs and to protect neuronal cells against glutamate neurotoxicity, which has 
been implicated in AD [8]. Specifically, it has been reported that stimulation of α4β2 nAChRs 
inhibits Aβ cytotoxicity [9]. Thus, α4β2 nAChRs are one of the potential therapeutic targets to 
prevent the pathological progress of AD. Several imaging probes have been developed to visualize 
α4β2 nAChRs using PET/SPECT, including 5-[123I]iodo-3-[2(S)-azetidinylmethoxy]pyridine 
([123I]5IA) [10] and 2-[18F]fluoro-3-[2(S)-azetidinylmethoxy]pyridine ([18F]2FA), and some clinical 
studies in normal subjects and patients have been already successfully performed. Conversely, the 
characterization of α7 nAChR radioligands such as [18F]ASEM and [18F]NS10743 is still in progress, 
and no clinical research in patients has been conducted yet.  
Several in vivo imaging studies using [18F]2FA or [123I]5IA in AD patients and age-matched 
healthy subjects have provided conflicting evidence regarding whether nAChR density is affected. 
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The majority of the available studies have shown significant reductions in tracer binding in AD 
[11-12]; however, there are some that have not [13]. A potential explanation for these heterogenous 
results is that clinical trials are directly affected by factors such as secondhand smoke and the 
varying combination of symptoms. As a complement to clinical studies, many types of transgenic 
mice have recently been developed with expressions of specific altered genes that relate to human 
diseases. Thus, studies using transgenic mice as animal models of AD would be more useful than 
clinical trials to elucidate directly whether the nAChR deficits occur in association with cognitive 
impairments or not.  
In this study, we aimed to investigate the age-related changes in cognitive function, cerebral 
glucose metabolism, and nAChR expression in the brain as the disease advances using an AD mouse 
model (APP/PS2 mouse). Our [125I]5IA-autoradiography (ARG) analysis showed that α4β2 nAChR 
deficits in the brains of APP/PS2 mice occurred when cognitive impairment was first observed. It 
was supported by a reduction in α4 nAChRs protein levels, as detected by western blotting. The 
[123I]5IA-SPECT analysis was sufficiently sensitive to assess the decline in α4β2 nAChRs in the 
brains of APP/PS2 mice at 12 months of age. Conversely, changes in glucose uptake and α7 nAChR 
expression were not associated with cognitive impairments in the AD model. This suggests that 
decreased α4β2 nAChRs density in the brain acts an imaging biomarker that reflects the state of 
cognitive function in AD. 
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Materials and methods 
Animals 
Animal experiments were performed in accordance with the guidelines of the Okayama 
University and Kyoto University Animal Care Committees. The experimental procedures performed 
were approved by both care committees. All studies were conducted with Tg2576×PS2 (APP/PS2) 
double-transgenic mice [14] and age-matched wild-type littermate controls. Male Tg2576 and female 
PS2 mice were purchased from Taconic Biosciences, Inc. (Hudson, NY, USA) and Oriental Yeast 
Co., Ltd. (Tokyo, Japan), respectively. To obtain APP/PS2 mice, Tg2576 mice were crossed with PS2 
mice.  
 
Materials 
Sodium [125I]iodide and sodium [123I]iodide were purchased from PerkinElmer (MA, USA) 
and FUJIFILM RI Pharma Co., Ltd. (Tokyo, Japan), respectively, and radioiodination of [123/125I]5IA 
was performed according to our previous report [15]. [3H]MK-801 were purchased from American 
Radiolabeled Chemicals Inc. (MO, USA). [18F]FDG was provided by Kyoto University Hospital 
(Kyoto, Japan). 
 
Novel object recognition test 
The novel object recognition (NOR) test was performed on all APP/PS2 and wild-type mice 
9 
used at 2, 6, 12, and 16 months of age (n = 9–21 per group) using a modification of the procedure by 
Oulès et al.[16]. This test was conducted in an open field (44 × 44 cm). Initially, the animals were 
habituated to the environment for 10 min/day for 3 days. On day 4, two identical objects (50-mL 
conical polypropylene tubes) were placed in the field, and animals were allowed to explore the 
objects for 10 min. On day 5, the animals were returned to the area with one familiar object (50-mL 
conical polypropylene tube) and one novel object (brown glass bottle) and allowed to explore the 
objects for 5 min. The time spent exploring each object was recorded and analyzed using ANY-maze 
software (Stoelting Co., IL, USA). An exploration preference (EP) index was calculated as follows: 
EP values (%) = time spent exploring the novel object / (time spent exploring the novel object + time 
spent exploring the familiar object) × 100. Animals that spent < 8 s exploring the objects during the 
10-min training session were omitted from the analysis (1–9 mice per group). 
 
Ex vivo dual autoradiography with [125I]5IA and [18F]FDG 
APP/PS2 and wild-type mice at 2, 6, 12, and 16 months of age (n = 4–5 per group) were 
deprived of food for 12–15 h after which the mice received injections of a mixture of [125I]5IA (700 
kBq) and [18F]FDG (23 MBq) via the tail vein. All mice were killed by decapitation 60 min after the 
injection. The brains were rapidly removed and frozen followed by slicing into 10 μm thick sections 
using a microtome. Two serial sections per brain region were exposed to an imaging plate (BAS IP 
SR; Fuji Photo Film, Tokyo, Japan) for 1 h together with the calibrated 18F standards ([18F]FDG 
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solution) to obtain [18F]FDG autoradiograms. After complete attenuation of the radioactivity of 18F, 
the radioactivity resulting from [125I]5IA was determined by exposure to a new imaging plate for 12 
h together with the calibrated 125I standards ([125I]5IA solution). Autoradiographic images were 
gained and analyzed as reported previously [10]. Two independent measurements were taken from 
the thalamus, cerebellum, striatum, cerebral cortex, hippocampus identified using a mouse brain 
atlas. The accumulation of radioactivity within regions of interest (ROIs) was calculated according to 
the following equation corrected for injection dose (MBq) and body weight (g): radioactivity 
accumulation (%ID*BW) = (radioactivity for each ROI) / (injected radioactivity / animal body 
weight) × 100. 
 
Histological staining of Amyloid β 
Upon completion of the ex vivo dual autoradiography study, serial sections were stained 
with thioflavin-S using the same procedure as that stated by Iikuni et al.[17]. The digital images (n = 
4 per group) taken under the same conditions were analyzed with BZ-X analyzer ver. 1.3.1.1 
software (Keyence Corp., Osaka, Japan). The area of interest of the hippocampus and cortex were 
manually outlined in each image, and the areas stained by thioflavin-S were quantified. 
 
SPECT/CT imaging 
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After injection of [123I]5IA (4.6–7.6 MBq) into each APP/PS2 and wild-type mouse (n = 4–
5) via the tail vein, dynamic SPECT/CT imaging was conducted using the same methods as those in 
our previous report [15]. For an accurate ROI definition, each mouse was subjected to magnetic 
resonance (MR) brain imaging one day prior to SPECT/CT imaging. Two spheroidal ROIs in the 
frontal cortex, striatum, hippocampus, thalamus, and cerebellum were positioned on MR images and 
then applied to SPECT images, as previously reported [15]. Standardized uptake values (SUVs) were 
calculated according to the following equation: SUV = radioactivity for each ROI (kBq/cc) / 
(injected dose [kBq] / body weight [g]) × 100. 
 
Immunoblotting 
The hippocampus of APP/PS2 and wild-type mice at 2, 12, and 16 months of age (n = 4 per 
group) were homogenized in a radioimmunoprecipitation assay buffer containing protease inhibitor. 
The electrophoresis and immunoblotting were performed via the same procedure as that stated by 
Oulès et al.[16]. The antibody resources and the details for application are shown in Supplemental 
Table 1. 
 
Statistical analysis 
GraphPad Prism ver. 7 (GraphPad, San Diego, CA, USA) was used for all statistical 
analyses. The comparisons between two groups were performed with student’s t-test. The statistical 
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data among 3 or more groups were assessed by analysis of variance (ANOVA) with a Bonferroni’s 
post-hoc test. Correlation coefficients were assessed using Pearson’s analysis. Differences with a P 
value < 0.05 were considered to be statistically significant. All data are expressed as mean ± 
standard deviation (SD).  
 
 
Results 
Amyloid load of APP/PS2 mice 
Figure 1 shows the time-dependent changes in Aβ deposition in the brains of APP/PS2 mice.  
The presence of Aβ plaques was first observed at 6 months of age. After 12 months of age, the 
amyloid-β plaque loads in the hippocampus and cortex were significantly increased compared to 2 
and 6 months of age (*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 between indicated 
groups, n = 4 mice per group). Conversely, no plaque was found in the wild-type mice at any age 
(data not shown).  
 
Novel object recognition test 
Figure 2 shows the time-dependent changes in cognitive abilities (expressed as EP values) 
of APP/PS2 and wild-type mice. No significant difference was found between the APP/PS2 and 
wild-type mice at 2–6 months of age in terms of novel object recognition memory. However, 
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APP/PS2 mice at 12 months of age showed a clear reduction in EP values as compared with those of 
wild-type mice (P < 0.0001), and APP/PS2 mice at 16 months of age showed the same level of 
cognitive deficit as at 12 months of age (P < 0.01). Conversely, no significant differences were found 
in EP values in wild-type mice at any age.  
 
Autoradiographic analysis of cerebral glucose metabolism 
Figure 3 shows the age-related changes in [18F]FDG uptake in each brain region of the 
APP/PS2 and wild-type mice. No significant differences were observed in any of the brain regions of 
the APP/PS2 mice at 2 months of age as compared with in wild-type mice. At 6 months of age, 
glucose uptake tended to increase in the cortex and hippocampus of APP/PS2 mice as compared with 
in wild-type mice. This tendency was terminated in all brain regions in APP/PS2 mice at 12 months 
of age, however, and at 16 months of age, glucose metabolism tended to decrease in the 
hippocampus and thalamus of APP/PS2 mice as compared with in the wild-type mice. However, 
these differences mentioned above were not statistically significant in any group. No age-related 
change in glucose metabolism was detected in the wild-type mice. 
 
Autoradiographic analysis of nAChR density 
Figure 4 shows age-related changes in [125I]5IA accumulation in all brain regions in the 
APP/PS2 and wild-type mice. The accumulation pattern of [125I]5IA in the brain of wild-type mice 
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was consistent with the known distribution pattern of α4β2 nAChRs with the highest accumulation in 
the thalamus; moderate in the striatum, hippocampus, and cerebral cortex; and the lowest in the 
cerebellum. No age-related change in [125I]5IA accumulation was detected in the wild-type mice.  
As compared with wild-type mice, no significant difference was observed in any of the 
brain regions examined at 2 months of age in APP/PS2 mice. At 6 months, [125I]5IA accumulation 
tended to increase in the hippocampus of APP/PS2 mice as compared with in wild-type mice, and 
showed almost the same levels in the other four brain regions as that noted in the wild-type mice. In 
12-month-old APP/PS2 mice, however, the [125I]5IA accumulation decreased in the cortex, 
hippocampus, and thalamus (P < 0.05, n = 4–5 per group) in comparison with the results seen in the 
wild-type mice. Decreases in [125I]5IA accumulation were maintained in all brain regions of the 
APP/PS2 mice at 16 months of age (striatum: P < 0.05, cortex: P < 0.01, hippocampus and thalamus: 
P < 0.0005, n = 4–5 per group). In contrast, no significant difference was found in [125I]5IA 
accumulation in the cerebellum in both groups at all the ages examined. 
 
 SPECT imaging with [123I]5IA 
Figure 5a shows SPECT/CT images of the APP/PS2 and wild-type mice obtained 56 min 
after injection of [123I]5IA. Images show slices at the frontal cortical, thalamic, and cerebellar levels, 
respectively. The accumulation pattern of [123I]5IA in the brains of wild-type mice was consistent 
with the known distribution pattern of α4β2 nAChRs. The averaged SUVs in each brain region of 
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both mice are shown in Figure 5b. The SPECT signals in the frontal cortex and hippocampus (P < 
0.01), and thalamus (P < 0.05) of APP/PS2 mice were lower than those detected in wild-type mice (n 
= 4–5 per group). In contrast, no significant difference was found in SUVs in the cerebellum. These 
findings were consistent with the results obtained in the ARG study. However, it should be noted that 
due to the low spatial resolution of SPECT images, radioactivity in the hippocampus, as determined 
by SPECT imaging, may be overestimated by the influence of high radioactivity in the thalamus. 
 
Expression levels of nAChRs 
To confirm that reduced [125I]5IA accumulation was detected in the brains of APP/PS2 mice 
at 12 and 16 months of age, we measured the protein levels of α4 and β2 nAChRs. As shown in 
Figure 6, the α4 subunit was reduced at the protein level by 30% (P < 0.01) in the hippocampus of 
APP/PS2 mice at 16 months of age as compared with in the wild-type mice at the same age. There 
were no significant differences in the protein levels of β2 nAChRs between the APP/PS2 and 
wild-type mice at any age. Additionally, reverse transcription polymerase chain reaction (RT-PCR) 
analyses revealed no significant change in the mRNA levels of α4 and β2 nAChRs in APP/PS2 mice 
at 2, 6, 12, or 16 months of age, as compared with wild-type mice of the same ages (Supplemental 
Figure 1). 
We also measured the protein levels (Figure 6) and the mRNA expression levels 
(Supplemental Figure 1) of α7 nAChR. APP/PS2 mice showed elevated α7 nAChR protein levels in 
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the hippocampus at 12 and 16 months of age (Figure 6, P < 0.01), and also showed elevated α7 
nAChR mRNA levels in the hippocampus at 2-16 months of age (2 months: P < 0.05, 6 months: P < 
0.01, 12 and 16 months: P < 0.0001, Supplemental Figure 1) in comparison with the wild-type mice. 
 
Autoradiographic analysis of NMDAR density 
The age-related changes in [3H]MK-801 binding in each brain region of the APP/PS2 and 
wild-type mice were evaluated and the results were shown in Supplemental Figure 2. No significant 
difference was observed in any brain region at any month of age in both mice. 
 
 
Discussion 
In this study, we explored the relationship between nAChR deficits, glycometabolism, and 
cognitive impairments in the presence of amyloid in an APP/PS2 AD mouse model. Double-tracer 
autoradiography (ARG) analysis and SPECT imaging study showed that [123/125I]5IA accumulation 
decreased in the cortex, hippocampus, and thalamus of 12-month-old APP/PS2 mice as compared 
with that recorded in the wild-type controls, i.e., at the age when cognitive impairments were first 
observed. Reductions in the protein levels of α4 nAChRs were also detected in the brains of 
16-month-old APP/PS2 mice using Western blotting. However, changes in glucose uptake and α7 
nAChR expression were not associated with cognitive impairment. 
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In the present study, we focused on nAChRs as targets for imaging biomarkers that might be 
used to identify the cognitive impairments induced by amyloid pathology, because nAChRs are 
reported to play an important role in cognitive function [5]. In addition, NMDARs are also reported 
to be involved in the cognitive impairments seen in AD, and are one of the targets for AD treatment 
[18]. Therefore, we evaluated the density of NMDARs in APP/PS2 mice using an in vitro ARG 
analysis of [3H]MK-801. However, no significant difference in [3H]MK-801 binding was observed 
between the APP/PS2 and wild-type mice (Supplemental Figure 2). These results suggest that rather 
than the density of NMDAR, the density of α4β2 nAChR might be a more sensitive biomarker for 
the cognitive impairments induced by amyloid pathology. 
The NOR test is a validated method for evaluating object cognition and recognition memory 
[16]. In the present study, APP/PS2 mice exhibited clear cognitive deficits at 12 and 16 months of 
age, when compared with wild-type mice. Using the Morris water maze test, Toda et al. reported that 
APP/PS2 mice exhibited impaired spatial learning and memory abilities at 4-5 months of age [14]. 
Impairment of spatial learning seems to occurr ealier than that of object recognition. This 
discrepancy is consistent with a previous report that cognitive impairment occurs in APP/PS1 and 
Tg2576 mice 1-13 months later when assessed by the NOR task rather than by the Morris water 
maze task [19]. Not all tasks have yielded similar findings, which may be a result of each task 
assessing different cognitive domains or behavioral aspects. It is possible that brain regions showing 
a decreased expression of α4β2 nAChRs in the present study are involved in object cognition and 
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recognition memory, not spatial learning. 
Our [18F]FDG-ARG analysis showed that glucose uptake increased in the cortex and 
hippocampus of APP/PS2 mice at 6 months of age as compared with wild-type mice. A previous 
[18F]FDG-PET study also reported significant cerebral hypermetabolism in APP/PS1 mice at six 
months of age [20]. Conversely, the increased glucose uptake that has been shown in several AD 
mouse models is clearly different from the decreased glucose uptake observed in human patients 
with AD. The reason for the discrepancy is unclear, but it is hypothesized that increased Ca2+ 
signaling and inflammatory responses by microglia and astrocytes affect glucose uptake [21]. 
Nine-month-old PS2APP mice are reported to show the first signs of an inflammatory response, as 
revealed by CD45 immunoreactivity and [3H]PK11195 binding analyses [22]. Thus, [18F]FDG might 
detect the neuropathological inflammatory response in the CNS. An electron microscopy study 
previously revealed the presence of extracellular Aβ and found that increased levels of insoluble Aβ 
were present in five-month-old APP/PS2 mice [14]. Characterization of the age-related changes in 
intraneuronal/extraneuronal oligomer deposition would provide further information on the 
relationship between glycometabolism and amyloid pathology in APP/PS2 mice. 
Since nAChRs are reported to be involved in higher brain function such as memory and 
recognition abilities, decreased α4β2 nAChR density could be used as a sensitive biomarker for 
cognitive impairments related to amyloid pathology. In this study, α4β2 nAChR deficits in the brains 
of APP/PS2 mice occurred at 12 months of age, which is when the cognitive impairment was first 
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observed. We found deficits in α4β2 nAChR at the protein level, but not at the genetic mRNA level. 
The discrepancy may be caused by alteration of nAChR synthesis on a different level, such as 
translation or post-translation modifications, or receptor turnover [23]. Conversely, the mRNA and 
protein levels of α7 nAChR subunits were significantly higher in the brains of APP/PS2 mice than in 
wild type mice. Interestingly, a reduction in α7 nAChR levels has been reported in the brains of 
patients with AD, while an increase in α7 nAChRs was recently detected in PC-12 cells exposed to 5 
μM Aβ1-42 [24]. Since at 6-7 months of age, PS2APP mice showed higher levels of insoluble Aβ1-42 in 
their brains than those observed in AD patients [14], it could be hypothesized that enhanced 
expression of α7 nAChR subunits was stimulated directly by higher concentrations of Aβ1-42. 
Moreover, α7 nAChRs are reported to be essential for inhibiting cytokine synthesis via the 
cholinergic anti-inflammatory pathway [25]. In the brain of patients with AD, α7 nAChRs may serve 
an anti-inflammatory role affecting neuropathological inflammation. This may be one of the reasons 
why α7 nAChRs were upregulated in the brain of APP/PS2 mice. The discrepancy between the 
decline in α4β2 nAChR subunits and increased density of α7 nAChR subunits would be an 
interesting focal point for AD pathology, and a potential topic for further studies. 
Our previous research provided the first evaluation of SPECT imaging of α4β2 nAChRs in 
the mouse brain [15]. In this study, the [123I]5IA-SPECT analysis was sufficiently sensitive to detect 
the decline in α4β2 nAChRs in the brains of APP/PS2 mice at 12 months of age. Therefore, 
measuring α4β2 nAChR density using [123I]5IA-SPECT may help in the evaluation of cognitive 
20 
abilities in AD mouse models, and in the screening of drugs targeting nAChRs.  
 
 
Conclusions 
The deficits of α4β2 nAChR in the brain of an AD mouse model (involving APP/PS2 mice) 
occurred at 12 months of age, which is when cognitive impairment was first observed. NAChR 
deficits could be noninvasively detected by [123I]5IA-SPECT in vivo. In contrast, no significant 
changes in glycometabolism, expression levels of α7 nAChRs, or NMDARs were associated with 
cognitive impairments in APP/PS2 mice. This result suggests that a reduction in α4β2 nAChR 
density in the brain might act as an imaging biomarker that reflects cognitive function in AD. 
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Fig. 3. Changes in [18F]FDG distribution in the brains of APP/PS2 mice. 
The y-axes indicate the accumulation of [18F]FDG radioactivity in each brain region. No significant 
difference in glucose metabolism was observed in any brain region in APP/PS2 mice at 2, 6, 12, or 
16 months of age as compared with in wild-type mice. Each point represents the average ± SD for 4–
5 mice. 
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Fig. 4. Changes in [125I]5IA distribution in the brains of APP/PS2 mice.  
The y-axes indicate radioactivity accumulation of [125I]5IA in each brain region. Notably, the 
APP/PS2 mice have a significant reduction in [125I]5IA accumulation in the cortex, hippocampus, 
and thalamus at 12 months of age (*P < 0.05 vs. wild-type) and in all brain regions at 16 months of 
age (*P < 0.05 in the striatum, **P < 0.01 in the cortex, and ***P < 0.0005 in the hippocampus and 
thalamus vs. wild-type). Each point represents the average ± SD for 4–5 mice. 
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Fig. 6. nAChRs protein levels in the hippocampus of APP/PS2 mice.  
The relative quantification of protein levels of α4, α7, and β2 nAChRs in the hippocampus of 
APP/PS2 mice at 2–16 months of age was measured by Western blotting. (a) Representative 
immunoblots and (b) summarized data of Western blot analyses in the hippocampus of APP/PS2 
mice. A significant decrease in α4 nAChRs levels was observed at 16 months of age (**P < 0.01 vs. 
wild-type) and a significant increase in α7 nAChRs was observed at 12 and 16 months of age (**P < 
0.01 at 12 and 16 months of age vs. wild-type). Values are expressed relative to β-actin, and each 
point represents the average ± SD for 4 mice. 
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Supplementary Methods 
RT-PCR analysis 
 APP/PS2 and wild-type mice at 2, 6, 12, and 16 months of age (n = 4 per group) were killed by 
cardiac puncture under anesthesia using 1.5–3% isoflurane. The brains were immediately removed and 
the hippocampus was isolated. RNA extraction, cDNA synthesis, and reverse transcription PCR 
(RT-PCR) were performed using the same procedure as that stated by Higashikawa et al. (1). The 
primer sequences, PCR product sizes, and accession number obtained from the Gene database are 
shown in Supplementary Table S2. The fluorescence intensities of the PCR products were quantitated 
using Image J software (NIH, MD, USA). The mRNA expression data was normalized to β-actin 
mRNA expression. 
 
Animal tissue preparation and autoradiography analysis of [3H]MK-801 
[3H]MK-801 were purchased from American Radiolabeled Chemicals Inc. (MO, USA). 
APP/PS2 and wild-type mice at 6, 12, and 16 months of age (n = 3–4 per group) were sacrificed by 
transcardial perfusion with phosphate buffered saline (PBS; pH 7.4) under anesthesia after 
completion of NOR analyses, and the brains were rapidly removed and frozen in a mixture of dry-ice 
and hexane (-75°C). Brain sections (10 μm thickness) were cut on a microtome and mounted on 
glass slides. The slides were dried at 25°C overnight and then stored at -80°C. 
Autoradiography analysis of the binding of [3H]MK-801 to NMDARs was performed using 
38 
a modification of the procedure by Velardo et al. (2). In brief, after preincubation, the sections were 
incubated for 120 min at 25°C in a buffer containing 10 nM [3H]MK-801 with 5 μM glycine and 5 
μM L-glutamine, followed by washing for a total time of 1 h with 3 changes of ice cold buffer. The 
dried sections were exposed to imaging plates (BAS IP TR, Fuji Photo Film) for 20 h together with 
the calibrated 3H standards. The data were expressed in fmol/mg as the mean ± SD for all mice. 
Non-specific binding was measured in adjacent serial sections by incubation with 200 μM 
(+)MK-801 and was subtracted from the total binding in each brain region.  
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Supplementary Tables 
 
Table S1. Resources of antibodies and details for applications  
Target catalog # antibody origin Source Dilution
α4 sc-5591 rabbit Santa Cruz 1:750 
β2 sc-11372 rabbit Santa Cruz 1:1000
α7 ab10096 rabbit Abcam 1:500 
β-actin sc-47778 mouse Santa Cruz 1:7500
The table shows the catalog number (#), antibody origin, source of antibody, and antibody dilution. 
 
 
 
Table S2. Primers used for the amplification of mouse nAChRs and β-actin 
Gene oligo sequence (5' → 3') 
Produ
ct size 
(bp) 
No 
α4 nAChR For CAGCTTCCAGTGTCAGACCA 230 NM_015730.5 
 Rev ATGGCCACGTATTTCCAGTC   
β2 nAChR For TGCTTTGTCAATCCTGCATC 199 NM_009602.4 
 Rev TGGCAACGTATTTCCAATCC   
α7 nAChR For TCTGATTCCGTGCCCTTGATAG 173 NM_007390.3 
 Rev CGCAGAAACCATGCACACC   
β-actin For CGGAACCGCTCATTGCC 300 NM_007393 
 Rev ACCCACACT GTGCCATCTA   
The table shows the nucleotide sequences, size of the amplified fragments in base pairs (bp), and the 
accession numbers (No) obtained from the Gene database.  
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